Live feed08:00:00·1862dPRReleasevia QuantisnowMedicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation's Subsidiary Chronix Biomedical, Inc.ByQuantisnow·Wall Street's wire, on your screen.OCX· Oncocyte CorporationHealth Care
